Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. Artiva Biotherapeutics was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, our mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva\'s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
06/30/20	$78,000,000	Series A	5AM Ventures GC LabCell Green Cross Medivate Partners RA Capital VenBio	undisclosed
03/02/21	$120,000,000	Series B	5AM Ventures Acuta Capital Partners Cormorant Asset Management EcoR1 Capital Franklin Templeton Janus Henderson Investors Logos Capital RA Capital Management RTW Investments Surveyor Capital Venrock Healthcare Partners Wellington Management Company	undisclosed